World's Best Scientists 2026 revealed!
Therapeutic Innovation and Regulatory Science
H-index 11

Therapeutic Innovation and Regulatory Science

2168-4790

Published by: Springer

https://www.springer.com/journal/43441

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 2656 54 47 8

Additional Metrics

Number of Best Scientists*: 90
Documents by Best Scientists*: 83
Top 100 Ranked Scientists*: 4
SCIMAGO H-index: 54
SCIMAGO SJR: 0.815
Impact Factor: 1.9

Overview

Top Research Topics at Therapeutic Innovation & Regulatory Science?

Pharmacy, Clinical trial, Pharmacotherapy, Drug development and Intensive care medicine are among the topics commonly tackled in the journal. Research in the field of Family medicine was used to conduct the presented Pharmacy study. In addition to Clinical trial research, the journal aims to explore topics under Clinical research, Randomized controlled trial, Medical physics, Risk analysis (engineering) and Protocol (science).

The research on Pharmacotherapy featured in the journal combines topics in other fields like Adverse effect and MEDLINE. Drug studies tackled cover an aspect of the field of Pharmacology.

  • Pharmacy (57.22%)
  • Clinical trial (27.32%)
  • Pharmacotherapy (19.87%)

What are the most cited papers published in the journal?

  • Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action (87 citations)
  • New Governmental Regulatory System for Stem Cell—Based Therapies in Japan (53 citations)
  • Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. (51 citations)

Research areas of the most cited articles at Therapeutic Innovation & Regulatory Science:

The published papers tackle a plethora of topics, such as Pharmacy, Clinical trial, Drug development, Clinical research and Public relations. While work presented in the most cited publications provide substantial information on Pharmacy, it also covers topics in Knowledge management, Alternative medicine, Pharmacotherapy and Pharmacology, Drug. In addition to Clinical trial research, the published articles aim to explore topics under Risk analysis (engineering), Management science, Protocol (science) and Medical education.

What topics the last edition of the journal is best known for?

  • Law
  • Internal medicine
  • Statistics

The previous edition focused in particular on these issues:

The journal focuses on Pharmacy, Clinical trial, Drug development, Pharmacotherapy and Process management. The journal explores studies in Pharmacy as part of the wider topic of Family medicine. The Clinical trial research presented in the journal explores the relationship between Oncology and the closely related topic of Oncology drug.

Issues in Drug development were discussed, taking into consideration concepts from other disciplines like Pharmaceutical industry and Agency (sociology). The journal explores issues in Pharmacotherapy which can be linked to other research areas like Adverse effect and MEDLINE. It holds forums on Process management that merges themes from other disciplines such as Quality (business) and Process (engineering).

The most cited articles from the last journal are:

  • Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19. (6 citations)
  • Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation. (4 citations)
  • Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice (4 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Therapeutic Innovation & Regulatory Science (based on the number of publications) are:

  • Kenneth A. Getz (33 papers) published 7 papers at the last edition, 5 more than at the previous edition,
  • J. Rick Turner (22 papers) published 1 paper at the last edition the same number as at the previous edition,
  • Stephen P. Spielberg (21 papers) absent at the last edition,
  • Mamoru Narukawa (18 papers) published 5 papers at the last edition, 3 more than at the previous edition,
  • Neil McAuslane (14 papers) published 1 paper at the last edition, 4 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Therapeutic Innovation & Regulatory Science (based on the number of publications) are:

  • Pfizer (79 papers) published 11 papers at the last edition, 4 more than at the previous edition,
  • Eli Lilly and Company (67 papers) published 5 papers at the last edition, 1 less than at the previous edition,
  • Food and Drug Administration (65 papers) published 9 papers at the last edition, 3 more than at the previous edition,
  • Center for Drug Evaluation and Research (60 papers) published 10 papers at the last edition, 4 more than at the previous edition,
  • Merck & Co. (60 papers) published 9 papers at the last edition the same number as at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 8.33% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 36.36% were posted by at least one author from the top 10 institutions publishing in the journal. Another 13.99% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 22.38% of all publications and 27.27% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Licensing Requirements

Another crucial aspect for researchers involved in therapeutic innovations and regulatory science, especially those considering a career in medical or pharmacy-related fields is understanding requirements for licensure. For instance, aspiring nursing professionals in Louisiana are required to meet certain criteria to obtain a license. Detailed information regarding these requirements can be found in our louisiana nursing license requirements guide. Meeting such licensure qualifications often necessitates continuous learning and contributions to the field, including research and publishing in renowned journals like Therapeutic Innovations and Regulatory Science.

Top Publications

  • Assessing the Financial Value of Decentralized Clinical Trials

    (2022)
    30 Citations
  • Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development

    (2022)
    26 Citations
  • Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative

    J Stephen Mikita;Jules Mitchel;Nicolle M Gatto;John Laschinger

    (2021)
    15 Citations
  • Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation

    (2022)
    13 Citations
  • Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.

    Trevor A Lentz;Lesley H Curtis;Frank W Rockhold;David Martin

    (2020)
    11 Citations
  • Determinants of Generic Drug Substitution in the United States

    (2020)
    10 Citations
  • Reasons for Premature Conclusion of Late Phase Clinical Trials: An Analysis of ClinicalTrials.gov Registered Phase III Trials

    (2020)
    10 Citations
  • Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring.

    Sylviane de Viron;Laura Trotta;Helmut Schumacher;Hans-Juergen Lomp

    (2021)
    9 Citations
  • An Innovative Health Literacy Approach Designed to Improve Patient Understanding of Medication Labeling

    (2021)
    8 Citations
  • Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers

    (2022)
    8 Citations

Related Online Degrees & Career Pathways

For those interested in Medicine, pursuing related degrees online can broaden career opportunities and deepen essential knowledge. Many students begin with an online biology programs to build a strong foundation in the life sciences before advancing to clinical studies.

Nursing is another critical path, with flexible options like asn online programs designed to fast-track entry into healthcare roles. These programs provide practical skills and often lead to becoming a registered nurse, complementing or serving as a stepping stone toward a medical degree.

Nutrition plays a vital role in patient care and preventive medicine. Students can explore health-focused disciplines through the best online nutrition programs, which cover dietetics, metabolism, and wellness strategies.

For those interested in healthcare administration, enrolling in online mha programs cahme accredited ensures quality education aligned with industry standards. This career pathway supports leadership roles critical to the efficient operation of medical facilities.

Best Scientists Contributing to This Journal